Group 1: R&D Progress - DR10624 has shown strong lipid-lowering effects and safety in Phase II clinical trials, with results presented at the AHA Scientific Sessions 2025. It has been included as a breakthrough therapy for severe hypertriglyceridemia by the CDE in January 2026 [1][2] - HDM1002, an oral GLP-1 receptor agonist, has completed patient enrollment for its Phase III trial in weight management, with top-line data expected in Q3 2026. The study has shown good overall safety without liver enzyme elevation [3] - HDM2005 has reported positive preliminary results in Phase I trials for mantle cell lymphoma and classical Hodgkin lymphoma, and is also undergoing trials for diffuse large B-cell lymphoma and solid tumors [4] Group 2: Upcoming Data Releases - Key data releases expected in 2026 include: - HDM1002 weight management Phase III top-line data - HDM1005 weight management Phase III 40-week data - HDM2005 solid tumor Phase I preliminary data - DR10624 for MASLD/MASH Phase II top-line data [5] Group 3: New Product Approvals and Market Outlook - The company anticipates new drug approvals in 2026, including edaravone tablets and various biosimilars, which are expected to enhance revenue contributions [6][7] - The innovative products, such as Ailaha® and Huijiaojing®, are projected to maintain rapid growth due to their clinical value and market strategies [9] Group 4: Industrial Microbiology and Pet Medicine - The industrial microbiology sector is expected to continue its rapid growth, supported by expanding overseas markets and commercialized products [12] - The HDM7006 project for managing obesity in cats is addressing a significant market gap, with a reported obesity rate of 28.1% among pet cats in China. This product is positioned as a safe and effective GLP-1/GIP dual-target weight management solution [16] Group 5: Strategic Collaborations and Licensing - The company is actively pursuing licensing agreements for its self-developed products and is optimistic about future collaborations [8] - A strategic partnership with MC2 for skincare products aims to leverage innovative technology for daily skin care solutions in the Greater China region [14][15]

Financial Performance - In the first half of 2025, the company achieved total revenue of CNY 21.675 billion, a year-on-year increase of 3.39% [2] - Net profit attributable to shareholders was CNY 1.815 billion, up 7.01% year-on-year [2] - The second quarter revenue reached CNY 10.939 billion, with a year-on-year growth of 3.65% [2] Pharmaceutical Sector Performance - The core subsidiary, China Medical East, reported revenue of CNY 7.317 billion, a 9.24% increase year-on-year, and a net profit of CNY 1.580 billion, up 14.09% [3] - The pharmaceutical industrial segment's innovative product sales reached CNY 1.084 billion, with a significant growth of 59% [3] Research and Development - The company invested CNY 1.484 billion in R&D, a 33.75% increase, with direct R&D expenses at CNY 1.174 billion, up 54.21% [4] - The R&D expenditure accounted for 15.97% of the pharmaceutical industrial revenue [4] - Over 80 innovative drug pipelines are currently under development, focusing on endocrine, autoimmune, and oncology fields [5][6] Product Pipeline and Innovations - The company is advancing several ADC products, including HDM2005 and HDM2012, with clinical trials ongoing [7][8] - In the autoimmune sector, candidates like HDM3018 and HDM4002 are in IND development, targeting conditions such as inflammatory bowel disease and IgA nephropathy [10][11] - The oral GLP-1 receptor agonist HDM1002 has completed patient enrollment for its clinical trials [15][20] Market Outlook and Strategic Initiatives - The company plans to distribute a cash dividend of CNY 614 million, representing 33.83% of the net profit [5] - The innovative product revenue is expected to continue rising, with a current contribution of nearly 15% to the pharmaceutical industrial revenue [14] - The newly established pharmaceutical investment fund will focus on innovative drugs, medical aesthetics, and health-related projects [19]